Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2013. The report serves as a regulatory update regarding a specific product development milestone rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on regulatory submissions and does not contain financial performance data.
Material Changes and Regulatory Updates
- US Submission: GSK submitted supplemental New Drug Applications (NDAs) to the US FDA for the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor).
- Indication: The combination is proposed for the treatment of adult patients with unresectable or metastatic melanoma harboring a BRAF V600 E or K mutation.
- Data Basis: Applications are supported by a randomised Phase I/II study comparing dabrafenib monotherapy against the combination therapy.
- Approval Status: The combination use is currently investigational and not approved anywhere in the world.
- European Status: The European review of the Marketing Authorization Application (MAA) for trametinib (monotherapy and combination) is ongoing. The CHMP has reverted from an accelerated assessment to standard timelines to allow sufficient review time.
Guidance, Risks, and Contingencies
The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. Specific operational risks are referenced in Item 3.D 'Risk factors' of the company's 2012 Annual Report on Form 20-F. No specific financial guidance or outlook is provided in this text.
Investor Verification Checklist
- Verify the FDA's acceptance and review timeline for the supplemental NDAs for the dabrafenib/trametinib combination.
- Monitor the status of the European CHMP review for trametinib, noting the shift to standard assessment timelines.
- Review the full US Prescribing Information for Tafinlar (dabrafenib) and Mekinist (trametinib) for approved uses and safety data.
- Consult the 2012 Form 20-F for detailed risk factors affecting GSK's operations.